Alice Breining1, Dominique Bonnet-Zamponi2,3, Lorène Zerah1,4, Carole Micheneau5, Nathalie Riolacci-Dhoyen5, Christine Chan-Chee6, Jean Deligne7, Jean-Marc Harlin8, Jacques Boddaert1,4, Marc Verny1,4, Armelle Leperre-Desplanques5. 1. APHP, DHU FAST, Groupe Hospitalier Pitié Salpêtrière - Charles Foix, Centre de Gériatrie, Paris, France. 2. OMEDIT Ile de France, Paris, France. 3. Université Paris Diderot, Sorbonne Paris Cité, UMR 1123 INSERM, Paris, France. 4. Sorbonne Universités, UPMC Univ Paris 06 and CNRS, UMR 8256 B2A, Paris, France. 5. HAS, Saint-Denis la Plaine, France. 6. French Institute for Public Health Surveillance, Saint-Maurice, France. 7. Régime Social des Indépendants, Saint Denis la Plaine, France. 8. Caisse Centrale de la Mutualité Sociale Agricole, Bagnolet, France.
Abstract
BACKGROUND: Little is known about the level of psychotropic chronic exposure in all patients living with dementia. The aim of the study was to quantify chronic psychotropic exposure in older adults with dementia compared with the general population of the same age. METHODS: This prospective cohort study was conducted in France between 2009 and 2011. Aged at least 65 years, 10,781,812 individuals (440,215 of them with dementia) either community based or nursing home residents were included. The numbers of single or combined prescriptions, per year for antipsychotics, antidepressants, anxiolytics, or hypnotics were measured. RESULTS: Of patients with dementia, 15.5% are exposed to antipsychotics compared with 2.2% of the age-matched population (relative risk [RR] = 6.44, 95% confidence interval [CI] [6.39-6.48]), 39.5% to antidepressants compared with 12.6% (RR = 4.10, 95% CI [.4.07-4.12]), and 39.6% to anxiolytics or hypnotics compared with 26.9% (RR = 1.74, 95% CI [1.72-1.75]). Among older adults with dementia, 13.8% simultaneously consumed at least three psychotropics. All class age of older patients with dementia is more exposed to all psychotropics except for long-acting benzodiazepines. During the study period, chronic anxiolytic/hypnotic and antipsychotic exposure slightly decreased in population with dementia while chronic exposure to antidepressant drugs tended to increase. CONCLUSION: This nationwide, population-based, drug-used study showed for the first time that older patients with dementia are chronically overexposed not only to antipsychotics but also to psychotropics.
BACKGROUND: Little is known about the level of psychotropic chronic exposure in all patients living with dementia. The aim of the study was to quantify chronic psychotropic exposure in older adults with dementia compared with the general population of the same age. METHODS: This prospective cohort study was conducted in France between 2009 and 2011. Aged at least 65 years, 10,781,812 individuals (440,215 of them with dementia) either community based or nursing home residents were included. The numbers of single or combined prescriptions, per year for antipsychotics, antidepressants, anxiolytics, or hypnotics were measured. RESULTS: Of patients with dementia, 15.5% are exposed to antipsychotics compared with 2.2% of the age-matched population (relative risk [RR] = 6.44, 95% confidence interval [CI] [6.39-6.48]), 39.5% to antidepressants compared with 12.6% (RR = 4.10, 95% CI [.4.07-4.12]), and 39.6% to anxiolytics or hypnotics compared with 26.9% (RR = 1.74, 95% CI [1.72-1.75]). Among older adults with dementia, 13.8% simultaneously consumed at least three psychotropics. All class age of older patients with dementia is more exposed to all psychotropics except for long-acting benzodiazepines. During the study period, chronic anxiolytic/hypnotic and antipsychotic exposure slightly decreased in population with dementia while chronic exposure to antidepressant drugs tended to increase. CONCLUSION: This nationwide, population-based, drug-used study showed for the first time that older patients with dementia are chronically overexposed not only to antipsychotics but also to psychotropics.
Authors: Jennifer A Watt; Tara Gomes; Susan E Bronskill; Anjie Huang; Peter C Austin; Joanne M Ho; Sharon E Straus Journal: CMAJ Date: 2018-11-26 Impact factor: 8.262
Authors: Philipp Hessmann; Jan Zeidler; Jona Stahmeyer; Sveja Eberhard; Jonathan Vogelgsang; Mona Abdel-Hamid; Claus Wolff-Menzler; Jens Wiltfang; Bernhard Kis Journal: Front Pharmacol Date: 2019-07-24 Impact factor: 5.810
Authors: Donovan T Maust; Julie Strominger; H Myra Kim; Kenneth M Langa; Julie P W Bynum; Chiang-Hua Chang; Helen C Kales; Kara Zivin; Erica Solway; Steven C Marcus Journal: JAMA Date: 2021-03-09 Impact factor: 56.272